Edwards Lifesciences Corporation $EW Shares Acquired by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. lifted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.5% in the second quarter, HoldingsChannel.com reports. The firm owned 13,000 shares of the medical research company’s stock after acquiring an additional 2,560 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Edwards Lifesciences were worth $1,017,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the stock. Journey Strategic Wealth LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter worth approximately $313,000. Franklin Resources Inc. raised its holdings in shares of Edwards Lifesciences by 22.1% in the 2nd quarter. Franklin Resources Inc. now owns 225,026 shares of the medical research company’s stock valued at $17,599,000 after buying an additional 40,795 shares during the period. MAI Capital Management lifted its stake in Edwards Lifesciences by 0.7% during the 2nd quarter. MAI Capital Management now owns 86,534 shares of the medical research company’s stock worth $6,768,000 after acquiring an additional 607 shares in the last quarter. Magnetar Financial LLC purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $7,305,000. Finally, Swiss National Bank grew its position in Edwards Lifesciences by 6.6% in the 2nd quarter. Swiss National Bank now owns 1,773,100 shares of the medical research company’s stock valued at $138,674,000 after acquiring an additional 109,600 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EW. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 29th. Jefferies Financial Group set a $98.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 price target for the company in a research note on Monday, November 3rd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price (up from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Price Performance

Shares of EW opened at $85.02 on Friday. The firm has a fifty day moving average price of $78.80 and a 200 day moving average price of $78.07. The stock has a market cap of $49.34 billion, a PE ratio of 12.23, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a 1-year low of $65.94 and a 1-year high of $87.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business’s revenue was up 14.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,020 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer owned 39,898 shares of the company’s stock, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.